Inflammatory phenotyping predicts clinical outcome in COVID-19 #MMPMID32962703
Burke H; Freeman A; Cellura DC; Stuart BL; Brendish NJ; Poole S; Borca F; Phan HTT; Sheard N; Williams S; Spalluto CM; Staples KJ; Clark TW; Wilkinson TMA
Respir Res 2020[Sep]; 21 (1): 245 PMID32962703show ga
BACKGROUND: The COVID-19 pandemic has led to more than 760,000 deaths worldwide (correct as of 16th August 2020). Studies suggest a hyperinflammatory response is a major cause of disease severity and death. Identitfying COVID-19 patients with hyperinflammation may identify subgroups who could benefit from targeted immunomodulatory treatments. Analysis of cytokine levels at the point of diagnosis of SARS-CoV-2 infection can identify patients at risk of deterioration. METHODS: We used a multiplex cytokine assay to measure serum IL-6, IL-8, TNF, IL-1beta, GM-CSF, IL-10, IL-33 and IFN-gamma in 100 hospitalised patients with confirmed COVID-19 at admission to University Hospital Southampton (UK). Demographic, clinical and outcome data were collected for analysis. RESULTS: Age > 70 years was the strongest predictor of death (OR 28, 95% CI 5.94, 139.45). IL-6, IL-8, TNF, IL-1beta and IL-33 were significantly associated with adverse outcome. Clinical parameters were predictive of poor outcome (AUROC 0.71), addition of a combined cytokine panel significantly improved the predictability (AUROC 0.85). In those
free
free
free
Respir+Res 2020 ; 21 (1): 245
